Breakthrough Innovations Transforming Lung Cancer Diagnosis and Treatment
Key Growth Drivers and Opportunities
Growing Global Lung Cancer Rate: Rising global lung cancer rate is a major driver of lung cancer market development, as it increases the demand for early identity, accurate diagnosis and effective treatment solutions. One of the major causes of cancer-related deaths worldwide with lung cancer, healthcare systems are making heavy investments in advanced screening tools such as low-dosage CT scans and biomarker-based diagnosis to enable the first diagnosis. At the same time, rising patient numbers are accelerating the development and adoption of innovative remedies including targeted drugs and immunotherapy. The burden of growing disease also attracts more research funds and industry investment, further fuel to market expansion.
Challenges
The lung cancer market faces several borders, including advanced diagnosis and high cost of targeted treatments, which can limit access to areas with especially low and moderate income. Delayed diagnosis also disrupts the results of treatment due to lack of awareness, limited screening programs and non-specific initial symptoms. Additionally, the challenge of complex regulatory routes, delayed stage patients, and the challenge of managing side effects from therapy disrupts the market growth despite technological progress.
Innovation and Expansion
EQUAL Study Launches High-Risk Group Lung Cancer Screening Trial
In May 2025, Researchers at the Dana-Farber Cancer Institute have begun testing a new, in-house blood test in an effort to screen for lung cancer and identify those who are at a higher risk of developing the disease even if they have never used tobacco.
Epidermal growth factor receptor (EGFR) gene mutations can be common in the Asian and Hispanic/Latinx populations, which is the subject of the EQUAL (EGFR ctDNA Quantitative Assessment for Lung Cancer screening in Asian and Latinx populations) study. Possessing this mutation increases the risk of lung cancer because EGFR type mutations are linked to the illness. Additionally, the number of cancer diagnoses among Asian or Hispanic/Latinx individuals is increasing at a faster rate.
With India's First LungLife Screening Program to Fight Lung Cancer, Apollo Cancer Centre Sets the Standard
In March 2025, India's first LungLife Screening Program for early lung cancer diagnosis has been introduced by Apollo Cancer Centres (ACCs), a pioneer in state-of-the-art cancer care. Lung cancer, which makes up 5.9% of all malignancies and 8.1% of cancer-related deaths in India, is the target of this ground-breaking project. Early identification increases the survival rate and improves treatment results (LINK).
Low-dose computed tomography (LDCT) early screening can greatly increase survival chances and help with early diagnosis. However, almost 80% of high-risk patients have never spoken to their doctors about screening. To allow early detection and save lives, it is imperative to improve knowledge and communication regarding lung cancer screening, particularly among high-risk individuals.
Inventive Sparks, Expanding Markets
The key players operating the lung cancer market include AstraZeneca, Hoffman La Roche, Eli Lilly and Company, Pfizer Inc., Merck & Co., Amgen Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb Company.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
TIME BUSINESS NEWS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a day ago
- Business Wire
Lura Health Announces Strategic Investment and Business Partnership with SCO Group to Advance Intraoral Health Monitoring
NEWARK, N.J.--(BUSINESS WIRE)-- Lura Health (UCHU Biosensors, Inc., Head Office: Newark, New Jersey, USA; CEO: Daniel Weinstein), a U.S. health tech company, today announced that it has entered into an investment and business partnership with SCO Group (Head Office: Chiyoda-ku, Tokyo, Japan; Chairman and CEO: Yusuke Tamai), a leading company in Japan's dental technology sector. The goal of the partnership is to deploy Lura Health's intraoral sensor technology into clinical use in Asia and expand its applications globally. Lura Health is developing wearable microsensors that can be worn inside the mouth, either attached to dental appliances or bonded directly to a tooth, to collect real-time biometric data such as pH levels and metabolites in saliva. The company is pioneering a new healthcare model that aims to "visualize whole-body health from within the oral cavity." Background and Purpose of the Partnership Lura Health has created the world's first continuous intraoral salivary monitoring sensor and is targeting medical device approval from the U.S. Food and Drug Administration (FDA) by early 2027. Following regulatory approval, Lura plans to expand its reach into Asian markets, starting with Japan. SCO Group is the operator of "Pay Light X," an integrated dental clinic management platform in Japan that supports appointment booking, diagnosis, payment, and aftercare. By integrating its sensor technology with SCO Group's clinical infrastructure, Lura Health aims to establish a new model for preventive health care in Japan. Key Points of the Partnership Continuous Monitoring with Intraoral Sensors Lura's sensors allow real-time monitoring of oral conditions such as pH and other salivary parameters. These measurements have the potential to supplement or replace conventional lab-based diagnostics in the future. Deployment through SCO Group's Platform By integrating with SCO Group's "Pay Light X," Lura aims to deliver its technology seamlessly to clinicians and patients. Joint pilot projects with Japanese universities and research institutions are expected to begin this fall to generate clinical validation and user feedback. Applications Beyond Dentistry Future use cases for the technology extend into sports performance monitoring, eldercare, and wellness, positioning Lura's sensors as a core tool in comprehensive personal health management. Statement from Daniel Weinstein, CEO of Lura Health "We at Lura Health are honored to announce our investment and business partnership with SCO Group, a leader in digital transformation within the Japanese dental industry. This collaboration represents a major step forward in our mission to enable preventive and user-friendly health monitoring through the diagnostic power of saliva. Our vision aligns deeply with SCO Group's commitment to improving the well-being of individuals through technology. Together, we will combine our sensor innovations with their extensive healthcare network to create tangible societal impact. We look forward to deploying our sensors in real-world clinical settings and co-developing patient-centered products based on live feedback from users in Japan." Partner Statement: Yusuke Tamai, Chairman and CEO of SCO Group "We are very pleased to partner with Lura Health, whose groundbreaking intraoral biosensing technology embodies the future of preventive healthcare. At SCO Group, we have long championed the integration of health technology into daily life, and this partnership allows us to take that mission to the next level. The oral cavity is a gateway to the body's health, yet remains one of the least-monitored areas. By utilizing saliva—a highly accessible source of biological data—we aim to convert invisible health risks into visible insights. Combined with our Pay Light X platform, we intend to build a comprehensive preventive care model that spans diagnosis, treatment, and everyday living." About Lura Health Lura Health is a U.S.-based medical device company developing intraoral microsensors that enable noninvasive, continuous monitoring of health biomarkers via saliva. Led by CEO Daniel Weinstein (Forbes 30 Under 30, Tufts University), the company specializes in microelectronics and biosignal processing and has drawn significant attention in fields such as oral health, diabetes, kidney disease, and therapeutic drug monitoring. LinkedIn:
Medscape
a day ago
- Medscape
Neuropathy Risk Influenced By Racial, Ethnic Disparities
TOPLINE: Known risk factors for peripheral neuropathy (PN) may explain the higher prevalence of the condition in non-Hispanic Black adults but not in Hispanic adults in the US, a new study showed. Researchers found that other factors may drive the disparity, including social determinants of health, such as food insecurity and a high percentage of total caloric intake from saturated fatty acids. METHODOLOGY: This cross-sectional secondary analysis included more than 8000 US adults (mean age, 61 years; 50% women) who participated in the National Health and Nutrition Examination Survey during 1999-2004. 55% of total participants were non-Hispanic White, 18% were non-Hispanic Black, 24% were Hispanic individuals, and 3% were of other races/ethnicities. Researchers assessed PN using a monofilament test for reduced sensation in both feet at three plantar locations: first metatarsal head, fifth metatarsal head, and the hallux. Demographic (age, sex, and race/ethnicity), metabolic (height, weight, waist circumference, systolic and diastolic blood pressure, and levels of high- and low-density lipoprotein cholesterol and A1c), and lifestyle (physical activity and diet) risk factors, as well as social determinants of health (food security, household income, and health insurance), were evaluated. TAKEAWAY: Higher age- and sex-adjusted odds of PN were observed in both Black (odds ratio [OR], 1.39) and Hispanic (OR, 1.31) participants than in White participants. Additionally, men had a higher risk for PN than women after age and race adjustment — but not after comprehensive adjustment. After adjusting for metabolic, lifestyle, and social determinants of health factors, Hispanic individuals maintained a higher likelihood of PN than White individuals (OR, 1.32; P = .001), while Black and White individuals had similar odds of PN (OR, 1.17; P = .17). Lack of health insurance (OR, 1.49), older age (OR, 1.05), taller height (OR, 1.03), higher levels of A1c (OR, 1.13), and larger waist circumference (OR, 1.01) were all associated with an increased risk for PN. Among Hispanic individuals specifically, food insecurity (OR, 1.48) and increased percentage of total caloric intake from saturated fatty acids (OR, 1.06) were linked to increased PN risk. IN PRACTICE: 'After comprehensively adjusting for known risk factors, we found that Black people had similar odds of neuropathy compared to White people, whereas Hispanic people continued to be at an increased likelihood of having neuropathy. Therefore, it is likely that unknown social risk factors exist for this population,' lead study author Evan Lee Reynolds, PhD, Michigan State University, East Lansing, Michigan, said in a press release. Authors of an accompanying editorial added that the findings 'are a call to action to continue to address the disproportionate exposure to modifiable risk factors in Black and Hispanic populations.' SOURCE: The study and the accompanying editorial were published online on July 16 in Neurology. The editorial was authored by Georgette Dib and Nicholas E. Johnson, Virginia Commonwealth University, Richmond, Virginia. LIMITATIONS: The study was retrospective, cross-sectional, and partly exploratory in nature and relied on self-reported data. Additionally, some data were missing, monofilament testing may have led to misclassification of PN, and assessment of triglyceride levels was performed only in 53% of participants. Study findings were not generalizable to other racial/ethnic groups or individuals with multiple races/ethnicities. DISCLOSURES: Several investigators reported receiving funding from the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, Andrea and Lawrence A. Wolfe Research Professorship, Robert E. Nederlander Sr. Program for Alzheimer's Research, Andrea and Lawrence A. Wolfe Brain Health Initiative Fund, A. Alfred Taubman Medical Research Institute, and the NeuroNetwork for Emerging Therapies. One investigator also reported consulting for DynaMed, receiving research and editorial support from the American Academy of Neurology, and providing medicolegal consultations. One of the editorialists reported having various ties with various sources, including pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Axios
2 days ago
- Axios
Washington parents face steep childbirth costs
Having kids is expensive in Washington state and giving birth is no exception, according to data from FAIR Health. Why it matters: Birth costs are just one of many financial burdens for new parents, with pediatrician and child care bills often following soon after. Washington also has some of the highest day care center prices in the country, with the average infant tuition topping $21,000 per year. By the numbers: The average in-network cost to give birth in Washington is about $17,400 for vaginal deliveries and $23,642 for cesareans, according to data from FAIR Health, a national independent nonprofit. For the few people who choose to give birth out-of-network, the average costs are even more staggering, at $31,219 for vaginal births and $47,648 for C-sections. Nationwide, the average total in-network cost of giving birth in the U.S. is about $15,200 for vaginal deliveries and $19,300 for C-sections. How it works: The amounts in the FAIR Health Cost of Giving Birth Tracker include delivery, ultrasounds, lab work and more. They reflect the total costs paid by patients as well as their insurance companies, as applicable. Financial responsibilities of insured patients are typically well below the total amount paid, with average out-of-pocket costs of just under $3,000 from 2018 to 2020, per a 2022 analysis by the Peterson Center and KFF. Between the lines: Black and Hispanic people paid more out-of-pocket for maternal care than Asian and white patients with the same insurance, per a study published earlier this year in JAMA Health Forum.
